Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
The great promise of antiviral peptides against SARS-CoV-2

The great promise of antiviral peptides against SARS-CoV-2

Novel SARS-CoV-2 variants partially resistant to infection- and vaccine-induced immunity, study finds

Novel SARS-CoV-2 variants partially resistant to infection- and vaccine-induced immunity, study finds

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO

Moffitt Cancer Center presents new data from dozens of clinical research studies at ASCO

FDA approves investigational monoclonal antibody therapy sotrovimab for COVID-19

FDA approves investigational monoclonal antibody therapy sotrovimab for COVID-19

Using Sotrovimab to treat COVID-19 early

Using Sotrovimab to treat COVID-19 early

Researchers repurpose pre-existing anti-SARS-CoV antibody to develop potent neutralizing antibody against SARS-CoV-2

Researchers repurpose pre-existing anti-SARS-CoV antibody to develop potent neutralizing antibody against SARS-CoV-2

B.1.617.2 variant of SARS-CoV-2 is partially resistant to antibody-mediated neutralization

B.1.617.2 variant of SARS-CoV-2 is partially resistant to antibody-mediated neutralization

Glycosylation a significant element in SARS-CoV-2 infection and vaccine design, says study

Glycosylation a significant element in SARS-CoV-2 infection and vaccine design, says study

Reducing COVID-19 burden with monoclonal antibodies and vaccination

Reducing COVID-19 burden with monoclonal antibodies and vaccination

Could GRP78 be a therapeutic target against COVID-19?

Could GRP78 be a therapeutic target against COVID-19?

New collaborative effort to produce anti-HIV monoclonal antibodies

New collaborative effort to produce anti-HIV monoclonal antibodies

Facets of SARS-CoV-2 infection and animal models

Facets of SARS-CoV-2 infection and animal models

Dupilumab considerably reduced asthma exacerbations in young children, shows VOYAGE trial

Dupilumab considerably reduced asthma exacerbations in young children, shows VOYAGE trial

Monoclonal antibody bamlanivimab reduces hospitalization and death in moderate-to-severe COVID-19

Monoclonal antibody bamlanivimab reduces hospitalization and death in moderate-to-severe COVID-19

Nanotechnology and COVID-19 diagnosis and treatment

Nanotechnology and COVID-19 diagnosis and treatment

Investigational drug reduced triglycerides in patients with severe hypertriglyceridemia, acute pancreatitis

Investigational drug reduced triglycerides in patients with severe hypertriglyceridemia, acute pancreatitis

Antibody to SARS-CoV-2 inhibits complement hyperactivation

Antibody to SARS-CoV-2 inhibits complement hyperactivation

SARS-CoV-2 B.1.617 variant shows modest resistance to vaccine-induced antibodies

SARS-CoV-2 B.1.617 variant shows modest resistance to vaccine-induced antibodies

Study reports new monoclonal antibodies with broad neutralizing capabilities against betacoronaviruses (including SARS-CoV-2)

Study reports new monoclonal antibodies with broad neutralizing capabilities against betacoronaviruses (including SARS-CoV-2)

Severe COVID-19 linked to genetic clotting predisposition

Severe COVID-19 linked to genetic clotting predisposition